These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30181415)

  • 21. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
    Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors.
    Dagi Glass LR; Lawrence DP; Jakobiec FA; Freitag SK
    Ophthalmic Plast Reconstr Surg; 2017; 33(5):e114-e116. PubMed ID: 27893585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
    Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
    Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.
    Corcoran RB; Atreya CE; Falchook GS; Kwak EL; Ryan DP; Bendell JC; Hamid O; Messersmith WA; Daud A; Kurzrock R; Pierobon M; Sun P; Cunningham E; Little S; Orford K; Motwani M; Bai Y; Patel K; Venook AP; Kopetz S
    J Clin Oncol; 2015 Dec; 33(34):4023-31. PubMed ID: 26392102
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
    Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
    J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.
    Fattore L; Malpicci D; Marra E; Belleudi F; Noto A; De Vitis C; Pisanu ME; Coluccia P; Camerlingo R; Roscilli G; Ribas A; Di Napoli A; Torrisi MR; Aurisicchio L; Ascierto PA; Mancini R; Ciliberto G
    Oncotarget; 2015 Sep; 6(28):24823-41. PubMed ID: 26208478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic Response to BRAF-MEK Combination Therapy in Cecal Neuroendocrine Carcinoma With BRAFV600E Mutation and Refractory Lactic Acidosis.
    Imperiale A; Latgé A; Schaff-Wendling F; Goichot B; Kurtz JE; Malouf GG
    Clin Nucl Med; 2018 Sep; 43(9):701-702. PubMed ID: 30036245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
    J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor suppressor miR-193a-3p enhances efficacy of BRAF/MEK inhibitors in BRAF-mutated colorectal cancer.
    Hiraide S; Takahashi M; Yoshida Y; Yamada H; Komine K; Ishioka C
    Cancer Sci; 2021 Sep; 112(9):3856-3870. PubMed ID: 34288281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
    Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
    J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both
    Nordmann TM; Juengling FD; Recher M; Berger CT; Kalbermatten D; Wicki A; Paasinen-Sohns A; Cathomas G; Tzankov A; Daikeler T
    Blood; 2017 Feb; 129(7):879-882. PubMed ID: 27940476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical response to dabrafenib plus trametinib in a pediatric ganglioglioma with
    Miller KE; Schieffer KM; Grischow O; Rodriguez DP; Cottrell CE; Leonard JR; Finlay JL; Mardis ER
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33637608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring
    Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R
    Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Tan J; Liu R; Zhu G; Umbricht CB; Xing M
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15846-15851. PubMed ID: 32561648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of BRAF
    Yamamoto G; Sakakibara-Konishi J; Ikari T; Kitai H; Mizugaki H; Asahina H; Kikuchi E; Shinagawa N
    J Thorac Oncol; 2019 May; 14(5):e97-e99. PubMed ID: 31027751
    [No Abstract]   [Full Text] [Related]  

  • 37. Efficacy of BRAF inhibitor and anti-EGFR antibody in colorectal neuroendocrine carcinoma.
    Nakano M; Shimada Y; Matsumoto Y; Saiki T; Zhou Q; Sasaki K; Moriyama M; Yoshihara K; Natsumeda M; Kuriyama Y; Takii Y; Watanabe G; Umezu H; Okuda S; Ikeuchi T; Wakai T; Saijo Y
    Clin J Gastroenterol; 2022 Apr; 15(2):413-418. PubMed ID: 35133626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BRAFi/MEKi in patients with metastatic melanoma: predictive factors of complete response.
    Ribero S; Malavenda O; Fava P; Astrua C; Marra E; Osella-Abate S; Sanlorenzo M; Caliendo V; Fierro MT; Quaglino P
    Future Oncol; 2019 Jan; 15(2):133-139. PubMed ID: 30196713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.
    Allen A; Qin ACR; Raj N; Wang J; Uddin S; Yao Z; Tang L; Meyers PA; Taylor BS; Berger MF; Yaeger R; Reidy-Lagunes D; Pratilas CA
    PLoS One; 2019; 14(6):e0217399. PubMed ID: 31158244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.